# Abaloparatide: a new anabolic therapy on the horizon.

> PubMed lists PMID 25987981 in BoneKEy reports as Journal Article, with publication-date metadata of 2015-04-29 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-25987981-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-03-09
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-25987981-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-25987981-abaloparatide-v1.json
- Content SHA-256: `69653012a2d17e43b5700346e0a5f8460d1721039795de2f736c60d0b4681e0b`

## Claims and source pins

### Headline

Abaloparatide: a new anabolic therapy on the horizon. ([`pubmed-observation-pmid-25987981-2022-03-09-526e04574c42`](#source-pubmed-observation-pmid-25987981-2022-03-09-526e04574c42))

### Summary

PubMed lists PMID 25987981 in BoneKEy reports as Journal Article, with publication-date metadata of 2015-04-29 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25987981-2022-03-09-526e04574c42`](#source-pubmed-observation-pmid-25987981-2022-03-09-526e04574c42))

### Paragraph 1

PubMed lists PMID 25987981 in BoneKEy reports as Journal Article, with publication-date metadata of 2015-04-29 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25987981-2022-03-09-526e04574c42`](#source-pubmed-observation-pmid-25987981-2022-03-09-526e04574c42))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-25987981-2022-03-09-526e04574c42`](#source-pubmed-observation-pmid-25987981-2022-03-09-526e04574c42))

## Sources

<a id="source-pubmed-observation-pmid-25987981-2022-03-09-526e04574c42"></a>
- **Abaloparatide: a new anabolic therapy on the horizon. · retained source version 1:2022-03-09:current:526e04574c420a20b3f41b1d39b683cb45e4425e19ae99d90daaa9082580b766** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/25987981/) (`pubmed-observation-pmid-25987981-2022-03-09-526e04574c42`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Abaloparatide: a new anabolic therapy on the horizon." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-25987981-abaloparatide-v1.json SHA-256: 69653012a2d17e43b5700346e0a5f8460d1721039795de2f736c60d0b4681e0b.